{"groups":[{"description":"Participants received 10 mg MK-8628/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG000","title":"AL 10 mg QD 14-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG001","title":"AL 20 mg QD 14-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG002","title":"AL 40 mg QD 14-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.","id":"FG003","title":"AL 20 mg BID 21-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG004","title":"AL 80 mg QD 14-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.","id":"FG005","title":"AL 40 mg BID 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG006","title":"AL 120 mg QD 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG007","title":"AL 120 mg QD 21-21"},{"description":"Participants received 160 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG008","title":"AL 160 mg QD 14-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG009","title":"AML de Novo 80 mg QD 14-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG010","title":"AML/MDS 80 mg QD 14-21"},{"description":"Participants received 10 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG011","title":"OHM 10 mg QD 21-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG012","title":"OHM 20 mg QD 21-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG013","title":"OHM 40 mg QD 21-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG014","title":"OHM 80 mg QD 21-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.","id":"FG015","title":"OHM 40 mg BID 21-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"FG016","title":"OHM 120 mg QD 21-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG017","title":"OHM 120 mg QD 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.","id":"FG018","title":"OHM 120 mg QD 5-7"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle.","id":"FG019","title":"OHM 120 mg QD 7-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"FG020","title":"OHM/DLBCL 80 mg QD 14-21"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"10"},{"groupId":"FG011","numSubjects":"5"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"5"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"3"},{"groupId":"FG019","numSubjects":"5"},{"groupId":"FG020","numSubjects":"15"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Adverse event-related"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Adverse event-unrelated"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Withdrawal of consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Stopped to receive bone marrow graft"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Disease progression and adverse event"}],"milestones":[{"achievements":[{"comment":"Number treated","groupId":"FG000","numSubjects":"3"},{"comment":"Number treated","groupId":"FG001","numSubjects":"3"},{"comment":"Number treated","groupId":"FG002","numSubjects":"4"},{"comment":"Number treated","groupId":"FG003","numSubjects":"3"},{"comment":"Number treated","groupId":"FG004","numSubjects":"4"},{"comment":"Number treated","groupId":"FG005","numSubjects":"8"},{"comment":"Number treated","groupId":"FG006","numSubjects":"7"},{"comment":"Number treated","groupId":"FG007","numSubjects":"6"},{"comment":"Number treated","groupId":"FG008","numSubjects":"6"},{"comment":"Number treated","groupId":"FG009","numSubjects":"18"},{"comment":"Number treated","groupId":"FG010","numSubjects":"16"},{"comment":"Number treated","groupId":"FG011","numSubjects":"5"},{"comment":"Number treated","groupId":"FG012","numSubjects":"3"},{"comment":"Number treated","groupId":"FG013","numSubjects":"4"},{"comment":"Number treated","groupId":"FG014","numSubjects":"7"},{"comment":"Number treated","groupId":"FG015","numSubjects":"6"},{"comment":"Number treated","groupId":"FG016","numSubjects":"7"},{"comment":"Number treated","groupId":"FG017","numSubjects":"3"},{"comment":"Number treated","groupId":"FG018","numSubjects":"5"},{"comment":"Number treated","groupId":"FG019","numSubjects":"5"},{"comment":"Number treated","groupId":"FG020","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"6"},{"groupId":"FG009","numSubjects":"18"},{"groupId":"FG010","numSubjects":"16"},{"groupId":"FG011","numSubjects":"5"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"4"},{"groupId":"FG014","numSubjects":"7"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"7"},{"groupId":"FG017","numSubjects":"3"},{"groupId":"FG018","numSubjects":"5"},{"groupId":"FG019","numSubjects":"5"},{"groupId":"FG020","numSubjects":"15"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study consisted of a dose escalation phase in participants with AL and OHM followed by and expansion phase in 3 cohorts: de novo acute myelocytic leukemia (AML), myelodysplastic syndrome (MDS) AML, and diffuse large B-cell lymphoma (DLBCL).","recruitmentDetails":"80 participants were enrolled in the acute leukemia (AL) cohort and 78 were treated. 61 participants were enrolled in the other hematological malignancies (OHM) cohort and 60 were treated."}